Alector Stock Surges 13% on Premium-Priced Equity Offering

3-line summary

• Alector shares jumped about 13% in Friday premarket trading after the company priced a registered direct offering of 36.6 million common shares at $2.05 per share — about a 7.3% premium to its October 15 closing price; the deal is expected to raise approximately $75.03 million before fees, with closing expected around October 19 subject to customary conditions.
• New and existing investors are participating, including TCGX, BVF Partners, ADAR1 Capital Management, and Deep Track Capital. Morgan Stanley and BTIG are acting as joint lead underwriters.
• Alector, headquartered in South San Francisco, develops therapies aimed at slowing progression of neurodegenerative diseases. Proceeds are earmarked for R&D, manufacturing of drug candidates, working capital, capital expenditures, and general corporate purposes, as well as potential acquisitions or strategic transactions involving complementary products, technologies, or businesses. The article attributed the share-price jump to the above-prior-close offering pricing but did not provide further analysis of the market reaction.

This summary is our own processing of the source article; see the source link below for full context.